T1411 Predictors of Clinical Response from a Phase 2 Multi-Center Efficacy Trial Using Rifaximin, a Gut-Selective, Nonabsorbed Antibiotic for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome

✍ Scribed by Ringel, Yehuda .; Zakko, Salam F.; Ferreira, Nelson L.; Bortey, Enoch; Wu, Tina; Courtney, Kecia; Forbes, William P.; Lembo, Anthony; Pimentel, Mark

• Book ID: 123056372
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 56 KB
• Volume: 134
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/S0016-5085(08)62565-2